SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU is trending due to its active and supportive community rallying behind its real-world applications and expanding brand. The community is focused on building and launching new businesses, with discussions highlighting the recent Amazon storefront launch for Kendu Spice. Community members express strong conviction in KENDU's long-term potential, emphasizing its growing ecosystem and real-world utility.

Cemtrex, Inc. engages in the provision of solutions in the technology industry. It operates through the following segments: Security, Industrial Services, and Cemtrex Corporate. The Security segment provides end-to-end security solutions to meet corporate, industrial, and governmental security challenges. The Industrial Services segment offers single-source expertise and services for rigging, millwrighting, in plant maintenance, equipment erection, relocation, and disassembly to diversified customers. The Cemtrex Corporate segment refers to the holding company of the other two segments. The company was founded on April 27, 1998 and is headquartered in Hauppauge, NY.

Cemtrex Inc.

Cemtrex ($CETX) is trending due to high volatility and speculation of a potential short squeeze, sparking intense interest from retail traders. Community chatter revolves around support levels and potential breakouts, fueled by the stock's low float and recent surge in volume. Some traders are drawing comparisons to other low-float runners, while cautioning others to watch out for a potential dump.

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Galectin Therapeutics Inc

GALT is trending as investors discuss preparations for a potential acquisition, including a recent switch in accounting firms, and speculate about buyout offers. Community members are analyzing insider selling patterns, suggesting they may be related to an upcoming material event or buyout. The possibility of FDA guidance and a buyout are key drivers in the stock's current momentum.

AlphaTime Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on September 15, 2021 and is headquartered in New York, NY.

AlphaTime Acquisition Corp

AlphaTime Acquisition Corp ($ATMC) is trending following shareholder approval of its merger with HCYC Group, a Hong Kong-based insurance brokerage, triggering a massive after-hours surge. The community is focused on the low float and potential for a significant squeeze, drawing comparisons to other recent high-flying, low-float stocks. Some traders are discussing potential price targets and overnight holds, while others urge caution, citing the inherent risks of low-float plays.

Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The firm's product pipeline includes Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Redwood City, CA.

Exicure Inc

XCUR is trending due to positive Phase 2 data for its multiple myeloma treatment, leading to significant after-hours momentum. Community discussions revolve around the potential for a short squeeze given the stock's low float and high short interest, while some caution about potential dilution. The impressive volume surge is also being compared to other recent high-flying, low-float stocks.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk ($NVO) is trending amid discussions about its Alzheimer's drug trial results and the competitive landscape in the weight loss market, particularly against Eli Lilly ($LLY). While some express frustration over the stock's performance and concerns about regulatory hurdles, others see the dip as a buying opportunity, anticipating FDA approval for its oral weight loss pill and highlighting the company's strong fundamentals and undervaluation relative to competitors.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak Co. is trending as the community discusses its potential for a significant upswing, fueled by a recent institutional investment and positive financial developments like pension reversion. Conversations revolve around Kodak's pivot towards pharmaceuticals and advanced materials, with many speculating about potential contracts and partnerships. Some investors are drawing parallels to past meme stock rallies and anticipating a substantial price increase.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

CVKD is trending as traders discuss its bullish technical indicators and potential breakout, focusing on its low float which could lead to significant price volatility. Community members are closely watching key resistance levels, anticipating a possible surge. Bullish sentiment is fueled by upcoming catalysts and the company's progress with its lead drug candidate.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA is trending as investors discuss upcoming catalysts like SG-001 data, potential label expansion, and anticipation for Q3 earnings, with some suggesting it's undervalued and a potential takeover target. Community members are closely monitoring the stock's technicals amid a recent downtrend, hoping for a reversal and increased institutional interest. Discussions also involve the company's buyback program and potential impact from broader market factors.

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

Structure Therapeutics Inc - ADR

GPCR is trending due to positive data for its oral GLP-1 aleniglipron, with community members highlighting its potential as a takeover target amid pharma interest in obesity drugs. Bullish sentiment revolves around the drug's efficacy and clean safety profile, leading to discussions about analyst target hikes and potential acquisitions by major players like PFE or MRK. Some traders are closely watching for pullback entry points, while others focus on potential analyst target hikes and comparisons to competitors like VKTX.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
